DOAC Dosing Options in Anticoagulation Prophylaxis for Cancer Outpatients

Inclusion is tied to a Khorana score of 2, indicating intermediate risk for clot formation.

Treatments are administered for a 6-month period.

The sponsor does not supply the study drug; instead, apixaban will be prescribed and dispensed through usual care channels, with decisions on continuation after the study left to participants and their clinicians.

• Purpose and scope: A pragmatic, randomized trial evaluates dosing strategies of apixaban to reduce venous thromboembolism (VTE) and mortality risk in cancer outpatients at intermediate VTE risk.
• Population and eligibility: Approximately 996 participants with solid tumors or lymphoma are initiating or recently starting cancer-directed therapy.
• Intervention arms and comparator: Participants are allocated to one of three groups:
• Group 1: Apixaban 2.5 mg taken twice daily (standard prophylactic dosing).
• Group 2: Apixaban 5 mg taken once daily (alternative, more convenient dosage).
• Group 3: No anticoagulant therapy (standard care).
• Study design characteristics: The trial is described as pragmatic, aiming to resemble routine clinical practice with minimal procedural burden.

• Primary questions: The study seeks to determine whether a once-daily apixaban regimen provides comparable protection against VTE and mortality relative to the standard twice-daily prophylaxis, and whether either apixaban dosing strategy offers advantages over no preventive anticoagulation.
• Outcomes tracked: Incidence of VTE events, major or serious bleeding events, and all-cause mortality during the 6-month follow-up.

The trial directly compares dosing paradigms to inform feasibility and safety of broader prophylaxis use.

• Rationale: While guidelines endorse anticoagulant prophylaxis for select cancer patients at elevated risk, uptake remains limited due to bleeding concerns and practical considerations.
• Practical relevance: If the once-daily dosing proves noninferior to the twice-daily approach and both outperform no anticoagulation, clinicians might adopt a simpler regimen to enhance adherence and real-world effectiveness in intermediate-risk populations.

• Enrollment and status: The study is currently recruiting, with an estimated enrollment of 996 participants.
• Milestones: Completion is projected for August 2035, reflecting a long-term follow-up horizon typical of pragmatic cancer prevention trials.

• Explicit limitations are not detailed in the provided content; however, as with pragmatic designs, generalizability may depend on how closely participating sites mirror routine practice, and the open-channel drug provision may influence adherence and real-world applicability.

It also notes that the study drug is not sponsor-provided, but filled through standard care pathways, a factor that may affect adherence and comparability across sites.

• The source does not provide granular data on demographic subgroups, tumor types, prior thrombosis history, or precise safety signals beyond the general outcome intentions.